Recent Research Analysts’ Ratings Changes for Dyne Therapeutics (DYN)

A number of research firms have changed their ratings and price targets for Dyne Therapeutics (NASDAQ: DYN):

• 9/30/2026 – Dyne Therapeutics had its “buy” rating reaffirmed by Cantor Fitzgerald.
• 9/30/2026 – Dyne Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $50.00 price target on the stock.
• 9/30/2026 – Dyne Therapeutics had its “buy” rating reaffirmed by Chardan Capital. They now have a $38.00 price target on the stock.
• 9/30/2026 – Dyne Therapeutics had its price target lowered by HC Wainwright from $50.00 to $32.00. They now have a “buy” rating on the stock.
• 9/29/2026 – Dyne Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $47.00 price target on the stock.
• 9/9/2026 – Dyne Therapeutics had its price target lowered by Morgan Stanley from $45.00 to $36.00. They now have an “overweight” rating on the stock.
• 9/9/2026 – Dyne Therapeutics had its price target lowered by Robert W. Baird from $30.00 to $26.00. They now have an “outperform” rating on the stock.
• 9/9/2026 – Dyne Therapeutics had its price target lowered by Royal Bank Of Canada from $35.00 to $30.00. They now have an “outperform” rating on the stock.
• 9/9/2026 – Dyne Therapeutics was downgraded by JPMorgan Chase & Co. from “neutral” to “underweight”. They now have a $10.00 price target on the stock, down from $17.00.
• 9/8/2026 – Dyne Therapeutics had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $37.00 price target on the stock.
• 8/17/2026 – Dyne Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
• 8/1/2026 – Dyne Therapeutics was downgraded by Wall Street Zen from “sell” to “strong sell”.

Insider Buying and Selling at Dyne Therapeutics

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 2,160,516 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $25.00, for a total value of $54,012,900.00. Following the completion of the sale, the director owned 428,946 shares of the company’s stock, valued at approximately $10,723,650. This trade represents a 83.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Cox sold 5,658 shares of the company’s stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $18.88, for a total transaction of $106,823.04. Following the transaction, the chief executive officer directly owned 357,507 shares in the company, valued at approximately $6,749,732.16. This trade represents a 1.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 3,376,157 shares of company stock valued at $83,290,469. 9.46% of the stock is owned by corporate insiders.

Dyne Therapeutics, Inc is a biotechnology company focused on developing treatments for genetically driven muscle diseases. The company uses its FORCE platform, which is designed to deliver oligonucleotide therapeutics to skeletal muscle and other tissues by combining muscle-targeting antibodies with genetic medicines.

Dyne’s research and development programs are aimed at conditions in which the underlying genetic mutations impair muscle function. Its pipeline has included DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy in patients with mutations amenable to exon 51 skipping.